Cancer Channel
Related Channels


Men who have prostate cancer that has spread or returned after previous treatment may receive a chemotherapy drug called enzalutamide. This prescription medicine comes as a capsule that is taken once a day. It works by preventing testosterone from stimulating the cancer. People who have a history of seizures, strokes, or certain other medical conditions may not be able to safely use this drug.


What Is Enzalutamide?

Enzalutamide (Xtandi®) is a prescription medication approved to treat castration-resistant prostate cancer that has spread to other parts of the body. Castration-resistant prostate cancer is prostate cancer that has returned or progressed despite medical or surgical treatments to lower testosterone levels. Enzalutamide is approved for use in men who have previously been treated with a chemotherapy medicine known as docetaxel (Docefrez™, Taxotere®).
(Click What Is Enzalutamide Used For? for more information on this topic, including possible off-label uses.)

Are There Side Effects?

As with any medicine, enzalutamide can cause side effects. However, not everyone who takes the drug will experience problems. Most people tolerate it quite well.
If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious reactions are less common.
Some of the most common side effects of enzalutamide include but are not limited to:
(Click Enzalutamide Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
7 Natural Ways to Reduce Your Cancer Pain

Enzalutamide Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.